Membrane complement regulators in RPE degeneration and retinal injury

RPE 变性和视网膜损伤中的膜补体调节因子

• 批准号: 8703115
• 负责人: Wenchao Song
• 金额: $ 49.36万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-08-01 至 2017-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8703115
• 关键词: Address; Age; Age related macular degeneration; Anaphylatoxins; Animal Model; Blindness; Blood Vessels; Breeding; CD46 Antigen; CD55 Antigens; Cell model; Cells; Cessation of life; Choroidal Neovascularization; Clinical Trials; Complement; Complement 3a; Complement 5a; Complement Activation; Complement Factor B; Complement Factor H; Complement Inactivators; Deposition; Development; Disease; Drusen; Elderly; Electroretinography; Eye; Eye diseases; Functional disorder; Fundus photography; Future; Gene Targeting; Genes; Genetic; Growth; High Prevalence; Homologous Gene; Host Defense; Human; Impairment; Individual; Injury; Knockout Mice; Link; Liquid substance; Mediating; Mediator of activation protein; Membrane; Modeling; Monoclonal Antibodies; Mus; Mutant Strains Mice; Natural Immunity; Nonexudative age-related macular degeneration; Optical Coherence Tomography; Oxidative Stress; Pathogenesis; Pathology; Pathway interactions; Penetrance; Phase; Phenotype; Photoreceptors; Play; Properdin; Proteins; Resistance; Retina; Retinal; Retinal Degeneration; Risk; Role; Route; Serum; Single Nucleotide Polymorphism; Staging; Structure of retinal pigment epithelium; Testing; Tissues; Transgenic Mice; animal model development; complement pathway; disease characteristic; drug candidate; geographic atrophy; human disease; inhibitor/antagonist; intravitreal injection; macula; mouse model; neutralizing monoclonal antibodies; novel; photoreceptor degeneration; pre-clinical; prevent; public health relevance; research study; risk variant

DESCRIPTION (provided by applicant): Complement is an important form of innate immunity that plays a key role in host defense. However, recent studies have revealed that it is also implicated in many human diseases, both rare and common. One of the high-prevalence diseases that have been linked to abnormal complement activation is age-related macular degeneration (AMD), a progressive blinding condition in the elderly. Genetic studies have provided evidence that individuals carrying single nucleotide polymorphism (SNP) in complement genes such as complement factor H (fH), factor B (fB), component 2 (C2) and component 3 (C3) are at increased risk of developing AMD. Although mouse models have been developed to study the role of complement in wet AMD with choroidal neovascularization (CNV) as an endpoint, and several anti-complement agents are being evaluated in clinical trials for wet AMD, better understanding of the role of complement in the development of dry AMD is required, and will be aided by development of animal models. RPE dysfunction is an overlapping pathological cause for both dry and wet AMD. In this project, we will study the pathogenesis of RPE dysfunction and retinal injury in the context of abnormal complement activation in the eye. We have created a mouse model by selectively deleting a key membrane complement regulator Crry in RPE cells. Crry is a murine C3 convertase inhibitor that is considered a functional homolog of human membrane cofactor protein (MCP, CD46). CD46 is down- regulated in the RPE in regions of expanding geographic atrophy (GA), making it a disease-relevant target. By using the cre-lox conditional gene targeting strategy, we selectively inactivated the Crry gene in RPE cells, modeling loss of CD46 in GA. Preliminary characterization of the RPE-specific Crry knockout (KO) mice revealed local complement activation together with features of RPE degeneration akin to human dry AMD. Furthermore, the mutant mice developed sub-RPE deposits and neurosensory retinal dysfunction. The RPE- specific Crry KO mouse thus represents a novel animal model that develops complement-mediated RPE degeneration/deposits with features of dry AMD. The overall objective of this proposal is to use the RPE- specific Crry KO mouse and investigate the mechanism of action of dysregulated complement in the pathogenesis of retinal degeneration, to define the complement mediators responsible and to explore anti- complement therapies for this disorder. These studies will help guide future anti-complement clinical trials with respect to effective complement cascade targets and routes of administration.

描述（由申请人提供）：补体是一种重要的先天免疫形式，在宿主防御中起关键作用。然而，最近的研究表明，它也与许多人类疾病有关，无论是罕见的还是常见的。与异常补体激活相关的高患病率疾病之一是年龄相关性黄斑变性（AMD），这是老年人的一种进行性致盲疾病。遗传学研究已经提供证据表明，在补体基因如补体因子H （fH）、因子B （fB）、组分2 （C2）和组分3 （C3）中携带单核苷酸多态性（SNP）的个体患AMD的风险增加。虽然已经建立了以脉络膜新生血管（CNV）为终点的小鼠模型来研究补体在湿性AMD中的作用，并且几种抗补体药物正在湿性AMD的临床试验中进行评估，但需要更好地了解补体在干性AMD发展中的作用，这将有助于动物模型的发展。RPE功能障碍是干性和湿性AMD的重叠病理原因。在这个项目中，我们将研究RPE功能障碍和视网膜损伤在眼睛补体异常激活的背景下的发病机制。我们通过选择性地删除RPE细胞中的关键膜补体调节因子Crry，建立了小鼠模型。Crry是一种小鼠C3转化酶抑制剂，被认为是人膜辅助因子蛋白（MCP, CD46）的功能同源物。CD46在扩张性地理萎缩（GA）区域的RPE中下调，使其成为与疾病相关的靶点。通过使用cre-lox条件基因靶向策略，我们选择性地灭活RPE细胞中的Crry基因，模拟GA中CD46的缺失。RPE特异性Crry基因敲除（KO）小鼠的初步表征显示，局部补体激活以及类似于人类干性AMD的RPE变性特征。此外，突变小鼠出现亚rpe沉积和神经感觉视网膜功能障碍。因此，RPE特异性的Crry KO小鼠代表了一种新的动物模型，其发展为补体介导的RPE变性/沉积，具有干性AMD的特征。本研究的总体目标是利用RPE特异性的Crry KO小鼠，研究失调补体在视网膜变性发病机制中的作用机制，确定补体介质的作用，并探索这种疾病的抗补体治疗方法。这些研究将有助于指导未来关于有效补体的抗补体临床试验